Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2011

Open Access 01-12-2011 | Research article

Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head

Authors: Hye- Ok Kim, Chang- Hoon Cho, Yoon- Je Cho, Seong- Ho Cho, Kyung- Sik Yoon, Kang- Il Kim

Published in: BMC Musculoskeletal Disorders | Issue 1/2011

Login to get access

Abstract

Background

The pathogenesis of osteonecrosis of the femoral head (ONFH) has been implicated in hypofibrinolysis and blood supply interruption. Previous studies have demonstrated that decreased fibrinolytic activity due to elevated plasminogen activator inhibitor-1 (PAI-1) levels correlates with ONFH pathogenesis. The -675 4G/5G single nucleotide polymorphism (SNP rs1799889) in the PAI-1 gene promoter is associated with PAI-1 plasma level. We investigated whether rs1799889 and two other SNPs of the PAI-1 gene (rs2227631, -844 G/A in the promoter; rs11178, +10700 C/T in the 3'UTR) are associated with increased ONFH risk.

Methods

Three SNPs in PAI-1 were genotyped in 206 ONFH patients and 251 control subjects, using direct sequencing and a TaqMan® 5' allelic discrimination assay. We performed association analysis for genotyped SNPs and haplotypes with ONFH.

Results

The 4G allele of rs1799889, A allele of rs2227631, and C allele of rs11178 were significantly associated with increased ONFH risk (p = 0.03, p = 0.003, and p = 0.002, respectively). When we divided the population according to gender, an association between the three SNPs and increased risk of ONFH was found only in men. In another subgroup analysis based on the etiology of ONFH, rs2227631 (A allele) and rs11178 (C allele) in the idiopathic subgroup (p = 0.007 and p = 0.021) and rs1799889 (4G allele) and rs11178 (C allele) in the alcohol-induced subgroup (p = 0.042 and p = 0.015) were associated with increased risk of ONFH. In addition, a certain haplotype (A-4G-C) of PAI-1 was also significantly associated with ONFH (p < 0.001).

Conclusion

Our findings demonstrated that three SNPs (rs1799889, rs2227631, and rs11178) of the PAI-1 gene were associated with ONFH risk. This study also suggests that PAI-1 SNPs may play an important role in ONFH.
Literature
1.
Zalavras C, Dailiana Z, Elisaf M, Bairaktari E, Vlachogiannopoulos P, Katsaraki A, Malizos KN: Potential aetiological factors concerning the development of osteonecrosis of the femoral head. Eur J Clin Invest. 2000, 30: 215-221. 10.1046/j.1365-2362.2000.00621.x.CrossRefPubMed
2.
Jones LC, Mont MA, Le TB, Petri M, Hungerford DS, Wang P, Glueck CJ: Procoagulants and osteonecrosis. J Rheumatol. 2003, 30: 783-791.PubMed
3.
Glueck CJ, Freiberg R, Tracy T, Stroop D, Wang P: Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis. Clin Orthop Relat Res. 1997, 334: 43-56.CrossRefPubMed
4.
Bjorkman A, Svensson PJ, Hillarp A, Burtscher IM, Runow A, Benoni G: Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res. 2004, 425: 168-172.CrossRefPubMed
5.
Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P: Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res. 2001, 386: 19-33.CrossRefPubMed
6.
Celik A, Tekis D, Saglam F, Tunali S, Kabakci N, Ozaksoy D, Manisali M, Ozcan MA, Meral M, Gülay H, Camsari T: Association of corticosteroids and factor V, prothrombin, and MTHFR gene mutations with avascular osteonecrosis in renal allograft recipients. Transplant Proc. 2006, 38: 512-516. 10.1016/j.transproceed.2005.12.062.CrossRefPubMed
7.
Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, Marti HP, Ganz R, Frey FJ, Kohler HP: Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation. 2002, 74: 1147-1152. 10.1097/00007890-200210270-00016.CrossRefPubMed
8.
Glueck CJ, Fontaine RN, Gruppo R, Stroop D, Sieve-Smith L, Tracy T, Wang P: The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop Relat Res. 1999, 366: 133-146.CrossRefPubMed
9.
Dawson S, Hamsten A, Wiman B, Henney A, Humphries S: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991, 11: 183-190. 10.1161/01.ATV.11.1.183.CrossRefPubMed
10.
Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995, 92: 1851-1855. 10.1073/pnas.92.6.1851.CrossRefPubMedPubMedCentral
11.
Asano T, Takahashi KA, Fujioka M, Inoue S, Ueshima K, Hirata T, Okamoto M, Satomi Y, Nishino H, Tanaka T, Hirota Y, Kubo T: Relationship between postrenal transplant osteonecrosis of the femoral head and gene polymorphisms related to the coagulation and fibrinolytic systems in Japanese subjects. Transplantation. 2004, 77: 220-225. 10.1097/01.TP.0000101433.99651.96.CrossRefPubMed
12.
Koo KH, Kim R, Kim YS, Ahn IO, Cho SH, Song HR, Park YS, Kim H, Wang GJ: Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. Clin Rheumatol. 2002, 21: 299-303. 10.1007/s100670200078.CrossRefPubMed
13.
Matsuo K, Hirohata T, Sugioka Y, Ikeda M, Fukuda A: Influence of alcohol intake, cigarette smoking, and occupational status on idiopathic osteonecrosis of the femoralhead. Clin Orthop Relat Res. 1988, 234: 115-123.PubMed
14.
Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D: Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost. 1987, 57: 67-72.PubMed
15.
Glueck CJ, Glueck HI, Mieczkowski L, Tracy T, Speirs J, Stroop D: Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis?. Thromb Haemost. 1993, 69: 460-465.PubMed
16.
Van Veldhuizen PJ, Neff J, Murphey MD, Bodensteiner D, Skikne BS: Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol. 1993, 44: 243-248. 10.1002/ajh.2830440405.CrossRefPubMed
17.
Su S, Chen S, Zhao J, Huang J, Wang X, Chen R, Gu D: Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease. Arterioscler Thromb Vasc Biol. 2006, 26: 948-954. 10.1161/01.ATV.0000204731.17646.f2.CrossRefPubMed
18.
Vaughan DE: PAI-1 and atherothrombosis. J Thromb Haemost. 2005, 3: 1879-83. 10.1111/j.1538-7836.2005.01420.x.CrossRefPubMed
19.
Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, Gray JW, Waldman FM, Ponder BA, Werb Z: Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev. 2006, 15: 2107-14. 10.1158/1055-9965.EPI-06-0351.CrossRefPubMedPubMedCentral
20.
Torres-Carrillo NM, Torres-Carrillo N, Vázquez-Del Mercado M, Delgado-Rizo V, Oregón-Romero E, Parra-Rojas I, Muñoz-Valle JF: The -844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis. Rheumatol Int. 2008, 28: 355-60. 10.1007/s00296-007-0453-z.CrossRefPubMed
21.
Hultman K, Tjarnlund-Wolf A, Odeberg J, Eriksson P, Jern C: Allele-specific transcription of the PAI-1 gene in human astrocytes. Thromb Haemost. 2010, 104: 998-1008. 10.1160/TH10-04-0243.CrossRefPubMed
22.
Kerachian MA, Sequin C, Harvey EJ: Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol. 2009, 114: 121-8. 10.1016/j.jsbmb.2009.02.007.CrossRefPubMed
23.
Powell C, Chang C, Gershwin ME: Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis. Clin Rev Allergy Immunol. 2010,
24.
Hong JM, Kim TH, Chae SC, Koo KH, Lee YJ, Park EK, Choi JY, Ryoo HM, Kim SY: Association study of hypoxia inducible factor 1alpha (HIF1alpha) with osteonecrosis of femoral head in a Korean population. Osteoarthritis Cartilage. 2007, 15: 688-694. 10.1016/j.joca.2006.12.007.CrossRefPubMed
25.
Kim TH, Baek JI, Hong JM, Choi SJ, Lee HJ, Cho HJ, Park EK, Kim UK, Kim SY: Significant association of SREBP-2 genetic polymorphisms with avascular necrosis in the Korean population. BMC Med Genet. 2008, 27 (9): 94-CrossRef
26.
Koo KH, Lee JS, Lee YJ, Kim KJ, Yoo JJ, Kim HJ: Endothelial nitric oxide synthase gene polymorphisms in patients with nontraumatic femoral head osteonecrosis. J Orthop Res. 2006, 24: 1722-1728. 10.1002/jor.20164.CrossRefPubMed
27.
Kim TH, Hong JM, Lee JY, Oh B, Park EK, Lee CK, Bae SC, Kim SY: Promoter polymorphisms of the vascular endothelial growth factor gene is associated with an osteonecrosis of the femoral head in the Korean population. Osteoarthritis Cartilage. 2008, 16: 287-291. 10.1016/j.joca.2007.06.017.CrossRef
28.
KIM TH, Hong JM, Oh B, Cho YS, Lee JY, Kim HL, Lee JE, Ha MH, Park EK, Kim SY: Association of polymorphisms in the Interleukin 23 receptor gene with osteonecrosis of femoral head in Korean population. Exp Mol Med. 2008, 40: 418-426. 10.3858/emm.2008.40.4.418.CrossRefPubMedPubMedCentral
29.
Kim TH, Hong JM, Shin ES, Kim HJ, Cho YS, Lee JY, Lee SH, Park EK, Kim SY: Polymorphisms in the Annexin gene family and the risk of osteonecrosis of the femoral head in the Korean population. Bone. 2009, 45: 125-131. 10.1016/j.bone.2009.03.670.CrossRefPubMed
30.
Bjorkman A, Burtscher IM, Svensson PJ, Hillarp A, Besjakov J, Benoni G: Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg. 2005, 125: 51-55. 10.1007/s00402-004-0760-8.CrossRefPubMed
31.
Zalavras CG, Vartholomatos G, Dokou E, Malizos KN: Genetic background of osteonecrosis: associated with thrombophilic mutations?. Clin Orthop Relat Res. 2004, 422: 251-255.CrossRefPubMed
32.
Glueck CJ, Freiberg R, Glueck HI, Tracy T, Stroop D, Wang Y: Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am J Hematol. 1995, 48: 213-220. 10.1002/ajh.2830480402.CrossRefPubMed
Metadata
Title
Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head
Authors
Hye- Ok Kim
Chang- Hoon Cho
Yoon- Je Cho
Seong- Ho Cho
Kyung- Sik Yoon
Kang- Il Kim
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2011
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-12-160

Other articles of this Issue 1/2011

BMC Musculoskeletal Disorders 1/2011 Go to the issue

Research article

Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis

Research article

Computed tomographic analysis of the quality of trunk muscles in asymptomatic and symptomatic lumbar discectomy patients

Research article

Effects of cyclosporin-a on rat skeletal biomechanical properties

Study protocol

Correlational analysis and predictive validity of psychological constructs related with pain in fibromyalgia

Research article

Written online situational feedback via mobile phone to support self-management of chronic widespread pain: a usability study of a Web-based intervention

Research article

Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions